Candel Therapeutics Files 8-K
Ticker: CADL · Form: 8-K · Filed: Apr 23, 2025 · CIK: 1841387
Sentiment: neutral
Topics: disclosure, financials
TL;DR
Candel Therapeutics filed a routine 8-K, no major news.
AI Summary
Candel Therapeutics, Inc. filed an 8-K on April 23, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements for this form.
Why It Matters
This 8-K filing indicates Candel Therapeutics is providing standard disclosures and financial information to the SEC, which is routine for public companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, not indicating any new risks or material changes.
Key Players & Entities
- Candel Therapeutics, Inc. (company) — Registrant
- April 23, 2025 (date) — Date of Report
- 001-40629 (other) — Commission File Number
- 52-2214851 (other) — IRS Employer Identification No.
- Needham, Massachusetts (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Candel Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on April 23, 2025.
What is Candel Therapeutics, Inc.'s Commission File Number?
Candel Therapeutics, Inc.'s Commission File Number is 001-40629.
Where are Candel Therapeutics, Inc.'s principal executive offices located?
Candel Therapeutics, Inc.'s principal executive offices are located at 117 Kendrick St Suite 450, Needham, Massachusetts, 02494.
Does this filing indicate any specific new financial results or material events?
This filing indicates it is for Regulation FD Disclosure and Financial Statements and Exhibits, but does not detail specific new financial results or material events within the provided text.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 23, 2025 regarding Candel Therapeutics, Inc. (CADL).